If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now?

Benzinga and Yahoo Finance LLC whitethorn gain committee oregon gross connected immoderate items done the links below.

AbbVie Inc. (NYSE:ABBV) engages successful the probe and development, manufacture, and merchantability of medicines and therapies worldwide.

It is acceptable to study its Q4 2025 net connected Jan. 30. Wall Street analysts expect the institution to station EPS of $3.36, up from $2.16 successful the prior-year period. According to Benzinga Pro, quarterly gross is expected to scope $16.39 billion, up from $15.10 cardinal a twelvemonth earlier.

Don't Miss:

• GM-Backed EnergyX Is Solving the Lithium Supply Crisis — Invest Before They Scale Global Production

• Buffett's Secret to Wealth? Private Real Estate—Get Institutional Access Yourself

The company's banal traded astatine astir $60.29 per stock 10 years ago. If you had invested $10,000, you could person bought astir 166 shares. Currently, shares commercialized astatine $232.32, meaning your investment's worth could person grown to $38,509 from banal terms appreciation alone. However, AbbVie besides paid dividends during these 10 years.

AbbVie's dividend output is presently 3.02%. Over the past 10 years, it has paid astir $48.95 successful dividends per share, which means you could person made $8,119 from dividends alone.

Summing up $38,509 and $8,119, we extremity up with the last worth of your investment, which is $46,628. This is however overmuch you could person made if you had invested $10,000 successful AbbVie banal 10 years ago. This means a full instrumentality of 366.28%. In comparison, the S&P 500 full instrumentality for the aforesaid play was 282.60%.

Trending: From Moxy Hotels to $12B successful Real Estate — The Firm Behind NYC's Trendiest Properties Is Letting Individual Investors In.

AbbVie has a statement standing of "Overweight" and a terms people of $232.65 based connected the ratings of 28 analysts. The terms people implies conscionable astir 0.1% imaginable upside from the existent banal price.

The institution connected Oct. 31 announced its Q3 2025 earnings, posting revenues of $15.78 billion, beating the statement of $15.59 billion, arsenic reported by Benzinga. Adjusted EPS came successful astatine $1.86, supra the statement estimation of $1.79.

AbbVie raised its full-year 2025 adjusted EPS to the scope of $10.61 to $10.65 from the anterior scope of $10.38 to $10.58, versus the statement estimation of $10.53.

Given the expected upside imaginable of conscionable astir 0.1%, growth-focused investors whitethorn not find AbbVie banal attractive. Conversely, the banal tin beryllium a bully enactment for income-focused investors, who tin payment from the company's coagulated dividend output of 3.02% and accordant hikes. AbbVie has raised its dividend consecutively for the past 12 years.